Estrella Immunopharma (NASDAQ:ESLA) Shares Down 2.5% – What’s Next?

Estrella Immunopharma, Inc. (NASDAQ:ESLA)’s stock price was down 2.5% during mid-day trading on Tuesday. The company traded as low as $0.4111 and last traded at $0.4290. 68,650 shares traded hands during trading, an increase of 63% from the average session volume of 42,244 shares. The stock had previously closed at $0.44.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 24th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Estrella Immunopharma currently has an average rating of “Hold” and an average price target of $8.00.

Estrella Immunopharma Stock Performance

The company has a market cap of $18.16 million, a price-to-earnings ratio of -1.74 and a beta of 0.93. The stock’s fifty day moving average is $0.63 and its two-hundred day moving average is $0.98.

Estrella Immunopharma (NASDAQ:ESLA) last posted its earnings results on Thursday, August 13th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.04. On average, equities research analysts expect that Estrella Immunopharma, Inc. will post -0.25 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Estrella Immunopharma stock. BlackRock Inc. acquired a new position in Estrella Immunopharma, Inc. (NASDAQ:ESLA) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 52,033 shares of the company’s stock, valued at approximately $54,000. BlackRock Inc. owned 0.12% of Estrella Immunopharma at the end of the most recent quarter. 0.35% of the stock is currently owned by hedge funds and other institutional investors.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc is a clinical-stage biopharmaceutical company focused on developing T-cell-based immunotherapies for cancer and other serious diseases. The company’s research is centered on chimeric antigen receptor T-cell (CAR-T) therapies, which are designed to genetically modify a patient’s immune cells so they can recognize and attack targeted cells.

Estrella’s lead program, EB-101, is an autologous CD19-directed CAR-T therapy being developed for the treatment of certain B-cell malignancies, including forms of leukemia and lymphoma.